A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Loncastuximab tesirine (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors ADC Therapeutics
- 22 Oct 2019 Planned End Date changed from 22 Feb 2020 to 18 Mar 2021.
- 22 Oct 2019 Planned primary completion date changed from 22 Feb 2020 to 24 May 2020.
- 22 Oct 2019 Status changed from recruiting to active, no longer recruiting.